Growth Hormone Deficiency in Mild Traumatic Brain Injury
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized control trial is to test if growth hormone therapy is a safe and
effective treatment for patients suffering from growth hormone deficiency and persistent
post-concussion symptoms. The main questions it aims to answer are:
1. Is growth hormone therapy effective at mitigating persisting post-concussion symptoms in
patients with growth hormone deficiency?
2. Is it feasible to conduct a larger trial to examine efficacy of growth hormone therapy
in patients with persistent post-concussion symptoms and growth hormone deficiency?
Participants will be asked to complete an initial assessment for study inclusion and to
complete clinical outcome questionnaires. If a participant meets study criteria they will be
randomized to receive either growth hormone therapy (provided by Pfizer) or a placebo
(provided by Pfizer). Participants will be instructed on how to self-administer their
assigned drug daily for three months. Monthly follow-up visits will include a blood draw to
measure a biomarker and clinical outcome questionnaires. At the final follow-up visit after
three months, participants will learn what group they were assigned and given the option to
complete the growth hormone therapy if they were originally assigned to the placebo group.
Researchers will compare the growth hormone therapy group to the placebo group to identify
any potential differences in outcomes.